Algert Global’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Algert Global’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,023	Closed	-$280K	–	446
2019 Q2	$280K	Sell	5,023 -13,945	-74%	-$727K	0.1%	237
2019 Q1	$958K	Sell	18,968 -2,811	-13%	-$125K	0.55%	53
2018 Q4	$877K	Buy	21,779 +15,636	+255%	+$806K	0.24%	140
2018 Q3	$426K	Buy	+6,143	New	+$466K	0.09%	267

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Algert Global's EGRX Position: Q3 2019 in Review

Algert Global sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2019, closing a stake of 5,023 shares — an estimated $280K sold.

Algert Global first reported a position in EGRX in Q3 2018 and held it in 4 quarters. The position peaked at $958K in Q1 2019. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

Algert Global reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Algert Global sold 5,023 Eagle Pharmaceuticals, Inc. shares in Q3 2019, an estimated $280K.
Algert Global first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and held it in 4 quarters.
Algert Global's Eagle Pharmaceuticals, Inc. position peaked at $958K in Q1 2019.
183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on Algert Global's 13F filing for Q3 2019, filed 14 Nov 2019.